Use our new account feature to register for a free CLI account. Your new account will allow you to bookmark and organize articles and research for easy reference later - making it simple to keep track of the research that's important to you!
Register / Sign in
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Filter Results By

Filter Applied. Clear All
Reset All Filters
Scholar

Eugene C. Tarne

Senior Analyst

Eugene C. Tarne is a senior analyst with the Charlotte Lozier Institute. He is also the president of Tarne Communications Inc., a communications and issue advocacy company he founded in 1999. For more than 25 years, beginning in 1989, Mr. Tarne served as a communications and media relations consultant to the United States Conference of Catholic Bishops Secretariat for Pro-Life Activities. In this capacity, he works closely with the Pro-Life Secretariat to develop messages, promote issues and legislation, develop new programs and materials and implement communications strategies designed to educate the public and promote pro-life issues in the public square. These issues include abortion, assisted suicide and euthanasia, and bioethical issues, especially cloning and stem cell research. In 1996, Mr. Tarne helped found the Physicians Ad Hoc Coalition for Truth (PHACT), an organization of doctors and other medical professionals formed to bring the medical facts to bear on the partial-birth abortion debate. Mr. Tarne also served as Communications Director for Do No Harm: The Coalition of Americans for Research Ethics, a coalition of scientists, researchers, bioethicists, medical, academic and other professionals, patient advocates, and concerned individuals, established in 1999, to promote the ethical pursuit of stem cell research and regenerative medicine in general, and to provide accurate information on such research. Mr. Tarne graduated from Georgetown University in 1977 with a B.A. in Theology. He received his M.A. in History of Religions from The George Washington University in 1979. He was offered scholarships to Harvard, the University of Chicago and the University of Pennsylvania to pursue a Ph.D. in South Asian Studies. He attended the University of Chicago and later the University of Pennsylvania, where he completed his Ph.D. studies, except for dissertation.

Research Authored

featured-image
Stem Cells & Therapies

Wiser Investment: Non-Embryonic Stem Cells Receive Millions from Maryland Fund

The state of Maryland is home to the Johns Hopkins University School of Medicine, one of the country’s leading stem cell research programs.   Maryland is also one of a handful of states to provide public funds for stem cell research, through

featured-image
Stem Cells & Therapies

Trends Show More Federal Funds Awarded to Non-Embryonic Stem Cell Research

Soon after then-President Clinton’s National Bioethics Advisory Committee (NBAC) in 1999 issued a report recommending federal funding for human embryonic stem cell research (hESCR) the subject of such funding became one of the nation’s most hotly contested public policy issues. It was

featured-image
Abortion

Minnesota Funds Progress through Adult & Induced Pluripotent Stem Cells

The third and most recent round of grants awarded earlier this year for stem cell research by the state of Minnesota tracks a pattern established with the two earlier rounds of grants: a noticeable lack of support for human embryonic stem cell

Stem Cells & Therapies

New Non-Embryonic Stem Cell Study Shows Progress with Parkinson’s Disease

Ever since human embryonic stem cells (hESCs) were first successfully grown in the lab in 1998, Parkinson’s Disease has featured prominently as one of the major diseases that such cells would supposedly eliminate.   

featured-image
End of Life

Netherlands Forcible Euthanasia Case and the Slippery Slope

Proponents of assisted suicide often dismiss “slippery slope” arguments on the grounds that proper safeguards will assure that assisted suicide will not devolve into euthanasia, either voluntary or not. Earlier this year, for example, Hawaii became another of several states to consider

Stem Cells & Therapies

Near Absence of Embryonic Stem Cells in California Clinical Trial Program

In 2013, the California Institute for Regenerative Medicine (CIRM) – the nation’s largest funder of stem cell research outside of the federal government – authorized a new program, the Alpha Stem Cell Clinics Network. The Network’s goal, according to CIRM, “is to

featured-image
Stem Cells & Therapies

Minnesota’s Funding of Stem Cell Research Echoes Trend toward Ethically Non-Contentious Approaches

In 2014, Minnesota became the most recent of a handful of states that provide state funding for all types of stem cell research, including human embryonic stem cell research. The law provides for 10 years of funding with $4.5 million approved for

Stem Cells & Therapies

Grants for Stem Cell Research Favor Ethical Approaches

The Maryland Stem Cell Research Fund (MSCRF) has awarded two rounds of grants since the Charlotte Lozier Institute last analyzed the Fund’s pattern of grant making for stem cell research, in the fall of 2013. That study found that since MSCRF first

Stem Cells & Therapies

iPSCs: A New Gold Standard in Regenerative Medicine?

A recent press release from the National Institutes of Health calls attention to a study, published in Stem Cell Reports, that researchers have “developed a clinical-grade stem cell line, which has the potential to accelerate the advance of new medical applications and

Stem Cells & Therapies

Next Station Stop: The Embryo Farm?

One of the earliest attempts to square this circle of trying to conduct morally problematic research within ethical guidelines is the “14-day rule” for embryo research. The rule has allowed embryo research outside the womb for up to 14 days post-fertilization, after